Kyparissia Sirinakis
Founder & Managing Partner @ Epidarex Capital
Bethesda, United States
Kyparissia Sirinakis is a seed investor at Epidarex Capital in Bethesda focused on Medical and Therapeutics. Ms. Sirinakis has more than twenty years of experience and a strong track record as an early-stage investor and senior executive in various health science and technology companies. Prior to co-founding Rock Spring Ventures, Ms. Sirinakis was a senior member of the MLSV management team where she actively managed several MLSV portfolio companies. Ms.Sirinakis was the Founder and Managing Director of WomenAngels.net LLC (“WAN”), a successful early-stage venture focused on the U.S. Mid-Atlantic region. WAN, a fund launched in 2000, generated a highly competitive Internal Rate of Return. WAN's success was driven by investing in highly disruptive technology platforms developed by strong management teams targeting large and unmet market needs. Ms. Sirinakis also has extensive experience working in the university environment as the Director of a technology accelerator and adjunct professor at George Mason University. She was the CFO for Oncologix, a Maryland venture-backed, early-stage biotechnology company which was subsequently sold to Antigenics, Inc. Ms. Sirinakis has held positions on the Board of Directors for numerous start-up companies throughout her career. She is a graduate of Boston College’s School of Management Honours Program and a Certified Public Accountant in the State of Maryland.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Kyparissia Sirinakis invests in
Stages Kyparissia Sirinakis invests in
Countries Kyparissia Sirinakis invests in
Investment Focus
Industry
- Medical 1 (100%)
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Slate Bio
|
Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics. | $1.8M / Seed / Jan 19, 2021 |
Co-Investors
Virginia Venture Partners
1 deal together
PharmaDirections
1 deal together
VTC Seed Fund
1 deal together
About Epidarex Capital
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Epidarex Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Roper
Partner
|
|||
Peter Finan
Partner
|
|||
Terri Burke
Venture Partner
|
|||
|
Kyparissia Sirinakis
Founder & Managing Partner
|
|||
|
Sinclair Dunlop
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kyparissia Sirinakis invest in?
Kyparissia Sirinakis invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kyparissia Sirinakis last invest?
The most recent investment recorded for Kyparissia Sirinakis closed in Jan 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
